Equities research analysts at JMP Securities began coverage on shares of Nuvectra (NASDAQ:NVTR) in a report released on Wednesday, Marketbeat reports. The brokerage set an “outperform” rating on the stock.
NVTR has been the subject of several other reports. Piper Jaffray Companies reissued a “hold” rating and set a $12.00 price target on shares of Nuvectra in a research report on Friday, November 3rd. ValuEngine raised shares of Nuvectra from a “strong sell” rating to a “sell” rating in a research report on Wednesday, January 31st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $12.00.
Nuvectra (NASDAQ:NVTR) traded up $0.48 during mid-day trading on Wednesday, hitting $10.74. 95,900 shares of the company’s stock traded hands, compared to its average volume of 116,944. Nuvectra has a 1-year low of $5.76 and a 1-year high of $15.00. The company has a quick ratio of 2.72, a current ratio of 2.90 and a debt-to-equity ratio of 0.37.
ILLEGAL ACTIVITY WARNING: “Nuvectra (NVTR) Receives New Coverage from Analysts at JMP Securities” was originally published by American Banking News and is the property of of American Banking News. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://www.americanbankingnews.com/2018/02/14/nuvectra-nvtr-coverage-initiated-at-jmp-securities.html.
Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company’s Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company’s commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs.
Receive News & Ratings for Nuvectra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra and related companies with MarketBeat.com's FREE daily email newsletter.